Market Place
Sourcing Support
Celltrion Spotlights Abpro`s ABP-102 at 44th JPM Conference
15 Jan 2026 //
GLOBENEWSWIRE
Abpro & Celltrion Gain FDA Clearance For Cancer Antibody ABP-102
06 Jan 2026 //
GLOBENEWSWIRE
Abpro Holdings Submits IND For Phase 1 Trial Of T Cell Engager
15 Dec 2025 //
GLOBENEWSWIRE
Abpro Extends Nasdaq Listing For Compliance And Strategy Pursuit
09 Dec 2025 //
GLOBENEWSWIRE
Abpro, Celltrion To Showcase Next-Gen HER2×CD3 T-Cell Engager
04 Nov 2025 //
GLOBENEWSWIRE
Abpro, Celltrion reveal data for ABP-102/CT-P72 at AACR 2025
27 Apr 2025 //
GLOBENEWSWIRE
Abpro to Present Preclinical Data on ABP-102/CT-P72 at AACR 2025
25 Mar 2025 //
GLOBENEWSWIRE
Abpro Statement on the Departure of Former CEO Ian Chan
10 Mar 2025 //
GLOBENEWSWIRE
Abpro Holdings Celebrates Nasdaq Bell Ringing Ceremony
12 Dec 2024 //
GLOBENEWSWIRE
Abpro Announces Filing of Registration Statement on Form S-4
22 Jan 2024 //
GLOBENEWSWIRE
Abpro inks SPAC deal to fund bispecific R&D years after axed IPO
22 Sep 2023 //
FIERCE BIOTECH
Abpro to Partnership with Celltrion for Development of a Antibody
22 Sep 2022 //
BUSINESSWIRE
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against
09 Dec 2021 //
GLOBENEWSWIRE
Abpro to present data at the 2021 ARVO of ABP201
04 May 2021 //
GLOBENEWSWIRE
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety
02 Feb 2021 //
GLOBENEWSWIRE
Abpro Announces Initiation of Phase 2/3 Studies of its Neutralizing
16 Dec 2020 //
GLOBENEWSWIRE
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy
16 Nov 2020 //
YAHOO
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.